BeStock  
Stocks › Drug Manufacturers - Specialty & Generic › PCRX

Pacira BioSciences PCRX

US equityMarket cap rank #3237Drug Manufacturers - Specialty & Generic
$25.20 +$0.44 (+1.78%)
Pre-market · Oct 8, 9:10 am ET · After hours $25.20 0.00%
Open$25.05
Prev close$24.76
Day range$24.99 – $26.00
Volume802.7K
Market cap$1.00B
P/E (TTM)72.0
Dividend yield–

Earnings

Average move on report day±4.1%last 16 reports
Closed higher8 of 1650% of the time
Best reaction+11.8%
Worst reaction-10.0%

Stock move on the day after each report

+3.1%2023/Q3-0.6%2023/Q4+11.8%2024/Q1+5.7%2024/Q2+0.2%2024/Q3-5.2%2024/Q4+0.8%2025/Q1-0.6%2025/Q2+4.5%2025/Q3-3.0%2025/Q4-4.1%2026/Q1-10.0%2026/Q2
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q24 Aug 2026After Market±11.0%-9.96%Within range
2026/Q130 Apr 2026After Market±12.2%-4.12%Within range
2025/Q426 Feb 2026After Market±13.1%-3.01%Within range
2025/Q36 Nov 2025After Market±16.5%+4.50%Within range
2025/Q25 Aug 2025After Market±11.8%-0.62%Within range
2025/Q18 May 2025After Market±12.2%+0.84%Within range
2024/Q427 Feb 2025After Market±14.8%-5.24%Within range
2024/Q36 Nov 2024After Market±13.3%+0.17%Within range
2024/Q230 Jul 2024After Market±36.6%+5.68%Within range
2024/Q17 May 2024After Market±12.4%+11.84%Within range
2023/Q429 Feb 2024Pre Market±14.9%-0.64%Within range
2023/Q32 Nov 2023Pre Market±7.1%+3.11%Within range
2023/Q22 Aug 2023Pre Market±16.7%+1.97%Within range
2023/Q13 May 2023Pre Market±13.1%-7.17%Within range
2022/Q428 Feb 2023Pre Market±13.8%+3.93%Within range
2022/Q33 Nov 2022Pre Market±11.5%-2.73%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q2

By business line

  • EXPAREL$147.82M 76.8%
  • ZILRETTA$32.65M 17.0%
  • iovera°$6.81M 3.5%
  • Bupivacaine liposome injectable suspension$3.22M 1.7%
  • Royalty revenue$1.91M 1.0%

Fundamentals

Full statements →

Latest reported quarter: Q2, ended Jun 2026

Revenue$192.40M+6.2% YoY
Operating profit$11.86M+29.9% YoY
Net profit$4.65M+196.0% YoY
Diluted EPS$0.12+209.1% YoY
Free cash flow$56.12M+502.5% YoY
Operating cash flow$57.46M

Revenue, last 8 quarters

$168.6MSep '24$187.3MDec '24$168.9MMar '25$181.1MJun '25$179.5MSep '25$196.9MDec '25$177.4MMar '26$192.4MJun '26

Net profit, last 8 quarters

$-143.5MSep '24$16.0MDec '24$4.8MMar '25$-4.8MJun '25$5.4MSep '25$1.6MDec '25$2.9MMar '26$4.7MJun '26

Profitability & balance sheet

Gross margin79.2%
Operating margin2.5%
Net margin2.0%
Return on equity2.0%
Return on assets1.1%
Return on invested capital1.1%
Current ratio5.04
Liabilities / assets46.0%
Cash & investments$251.03M
Total debt$401.82M
Net cash (debt)-$150.79M
Free cash flow / sales24.1%

Discussion

No comments yet — be the first to weigh in on PCRX.

Leave a comment

Scroll to Top